Company Overview and News

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 20-F/A

2018-03-29 sec.gov
20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A
Upvote Downvote

 
Analyzing CRISPR Therapeutics' Q4 And Full-Year 2017 Results

2018-03-20 seekingalpha
Editor's note: Seeking Alpha is proud to welcome SA Joseph Sancio as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Upvote Downvote

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-03-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
Upvote Downvote

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-03-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
Upvote Downvote

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-03-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
Upvote Downvote

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities IRANNOTICE

2018-03-08 sec.gov
IRANNOTICE U.S. Securities and Exchange Commission ING Groep N.V.
Upvote Downvote

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 20-F

2018-03-08 sec.gov
20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F
Upvote Downvote

 
Compugen Ltd.: An Undervalued Disruptive Innovation Company

2018-02-20 seekingalpha
Compugen Ltd. is an Israeli based company using advanced predictive discovery methods to identify novel drug targets in cancer immunotherapy and other disease treatments.
Upvote Downvote

5
Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

2018-02-06 seekingalpha
Today we will discuss AMAG Pharmaceuticals (AMAG), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia (IDA) who are intolerant of or have not responded adequately to oral iron therapy.
Upvote Downvote

3
Could CohBar Inc. Hold The Key To Treating Age-Related Disease?

2018-01-24 seekingalpha
CohBar Inc. is the first company exploring the field of mitochondrial derived peptides as a treatment to age related disease.
Upvote Downvote

 
Pound Halts Winning Streak as Seven-Day Rally Seen Overblown - Bloomberg

2017-11-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Russians Cold on Prices Despite Cheaper ‘Herring Under Fur Coat’ - Bloomberg

2017-11-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
How Strategists Are Trading Crude's Moves in Asia Currencies - Bloomberg

2017-11-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Noble Group Loses Key Bank Support as DBS Cuts Lending - Bloomberg

2017-11-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Deutsche Bank Pushes Ahead With a $2.3 Billion Offering - Bloomberg

2017-11-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 456837301